Fewer drugs are making it to market, while development costs continue to skyrocket. StemoniX provides solutions in partnership with leading biopharma, academic, and government institutions. Our functional models, expert services, and advanced analytical algorithms converge to provide the right biology, effective workflows, and actionable results that move our partners forward and get medications to patients faster.
Together, we can make medicines work the first time.
Human-first discovery that identifies new targets and treatments in high-throughput with human iPSC-derived organoid models.
DE-RISK DRUG
DISCOVERY
microOrgan Technology
®
Complex human biology for complex questions
StemoniX’s microOrgan plates contain ready-to-use functional microtissues engineered from human induced pluripotent stem cells (iPSC). Designed to enable high-throughput human drug screening without the need for drugs to enter a human body, our microOrgans offer significant cost and time savings for our partners.
Bringing Human Biology to the Bench
ANALYTIX
TM
Functional data needs complex analysis.
Get more valuable information from every experiment! At the intersection of human biology and AI, our Assay AnalytiX platform provides a deeper dive, faster return, and more robust data.
SERVICES
Partner with us for highly consistent, reproducible, and functional platforms.
DISCOVERY AS A SERVICE
(DAAS)
Sometimes, you just don't have the time or the staff to complete all of the work that needs to be done. We can help. From design to screening to analysis, outsource your discovery with our team of experts.
DISEASE MODELING
iPSCs retain the genetic makeup of the donor cells. Use one of our off-the-shelf disease models, or have us create a custom model just for your discovery needs.
PARTNERSHIPS & COLLABORATIONS
The same thinking leads to the same results. At StemoniX, we're always asking how we can do it better. Our
technology enables new questions and lower development costs. Most importantly, medicines are getting to patients faster than ever before. Join us.
